| Code | CSB-RA004936MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to reference antibody 2141-V11, targeting CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is a costimulatory protein expressed on antigen-presenting cells, including B cells, dendritic cells, and macrophages, playing a critical role in adaptive immune responses. Upon binding with its ligand CD40L (CD154), CD40 initiates signaling cascades that regulate B cell activation, immunoglobulin class switching, germinal center formation, and T cell priming. Dysregulation of CD40 signaling is implicated in various pathological conditions, including autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis, as well as hematological malignancies and solid tumors where it influences tumor microenvironment interactions.
2141-V11 is a fully humanizedized IgG1 monoclonal antibody with its Fc segment engineered. It binds to CD40 with high affinity, mimicking and enhancing the natural signal, thereby specifically activating the immune pathways mediated by CD40. This biosimilar provides researchers with a reliable tool for studying CD40 biology, exploring therapeutic targeting strategies, and advancing understanding of immune regulation in disease contexts.
There are currently no reviews for this product.